Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

High materiality7/10

Tempus AI Q2 Beat; guidance raised, but growth pace under scrutiny

Jul 30, 2026, 5:26 PM EDT2 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Despite a beat, the stock traded lower after-hours as investors weighed slower near-term growth and only modest guidance uplift, plus integration risk from the PRSN deal.

AI summary

What happened, with direct paths to the underlying reporting

Tempus AI posted Q2 revenue of $382.5M, up 22% YoY and above estimates, with Diagnostics at $289.3M and Data & Applications at $93.2M. The company raised full-year revenue guidance to about $1.595–$1.605B and targets roughly $65M in adjusted EBITDA, excluding the planned Personalis acquisition. After-hours shares fell as investors weighed near-term growth against the long-term AI-driven opportunity.

Q2 revenue 382.5M, +22% YoY; beat estimates.
Diagnostics revenue 289.3M, +20% YoY; Data & Applications 93.2M, +28%.
EPS -0.04 vs -0.14 expected.
Raised full-year revenue guidance to 1.595–1.605B.
Acquisition of Personalis expected to close late 2026/early 2027.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Tempus AI Q2 Beat; guidance raised, but growth pace under scrutiny

Tempus AI Rises on Merck–Moderna Trial Headlines; Short-Term Momentum

Tempus Expands AI Integration and Collaboration with Merck

Needham Analyst Reiterates Buy Rating with $75 Target for Tempus AI

TEM Reports Strong Earnings Growth and New Product Launch